Sun Pharma Advanced Research Company Limited (SPARC) reported revenue of ₹39.92 Cr and a net loss of ₹20.78 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
The statements below are read from Sun Pharma Advanced Research Company Limited’s filed results, 11 filed quarters and 3 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Aug 11, 2026 · audited
| ₹ Cr | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026Latest | YoYlatest |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.2 | 13.9 | 16.6 | 16.8 | 12.9 | 14.9 | 27.2 | 9.64 | 7.86 | 8.45 | 39.9 | n/m |
| 113 | 116 | 122 | 110 | 116 | 88.6 | 80.4 | 61.7 | 73.6 | 65.1 | 73.9 | +19.8% | |
| Operating profit | -91.5 | -103 | -106 | -93.4 | -103 | -73.7 | -53.2 | -52.1 | -65.7 | -56.6 | -34.0 | n/m |
| OPM % | -431.9% | -740.4% | -639.1% | -555.4% | -800.2% | -494.2% | -195.6% | -540.2% | -836.1% | -670.3% | -85.2% | +455.1 pp |
| Other income | 8.49 | 6.39 | 4.40 | 1.56 | 0.04 | 0.19 | 0.00 | 9.14 | 0.01 | 0.00 | 23.7 | +158.9% |
| Interest | 0.26 | 0.26 | 0.91 | 0.56 | 1.14 | 2.80 | 4.54 | 6.19 | 7.52 | 8.78 | 8.13 | +31.3% |
| Depreciation | 3.18 | 3.16 | 3.07 | 3.14 | 3.16 | 3.14 | 2.95 | 2.68 | 2.56 | 2.57 | 2.20 | -17.9% |
| Profit before tax | -86.4 | -99.7 | -105 | -95.5 | -107 | -79.4 | -60.7 | -51.8 | -75.8 | -80.4 | -20.7 | n/m |
| Tax % | n/a (loss) | n/a (loss) | n/a (loss) | n/a (loss) | n/a (loss) | n/a (loss) | n/a (loss) | n/a (loss) | n/a (loss) | n/a (loss) | n/a (loss) | — |
| Net profit | -86.4 | -99.7 | -106 | -95.9 | -107 | -79.5 | -59.8 | -51.9 | -75.9 | -80.4 | -20.8 | n/m |
| EPS (₹) | -2.66 | -3.07 | -3.26 | -2.96 | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 | -2.48 | -0.64 | n/m |
